Virtus ETF Advisers LLC Buys 936 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Virtus ETF Advisers LLC boosted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 24.7% during the 4th quarter, HoldingsChannel reports. The fund owned 4,733 shares of the biotechnology company’s stock after acquiring an additional 936 shares during the quarter. Virtus ETF Advisers LLC’s holdings in AnaptysBio were worth $63,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after buying an additional 644 shares in the last quarter. Rhumbline Advisers lifted its position in AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock worth $398,000 after buying an additional 1,111 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio during the 4th quarter worth about $40,000. Finally, Swiss National Bank lifted its position in AnaptysBio by 12.1% during the 4th quarter. Swiss National Bank now owns 29,700 shares of the biotechnology company’s stock worth $393,000 after buying an additional 3,200 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and set a $22.00 price target on shares of AnaptysBio in a research report on Tuesday, March 4th. Wells Fargo & Company upped their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a report on Wednesday, March 26th. Finally, Wolfe Research initiated coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $33.63.

AnaptysBio Stock Performance

Shares of ANAB opened at $21.33 on Tuesday. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $41.31. The firm has a market cap of $654.13 million, a P/E ratio of -3.51 and a beta of -0.09. The firm’s 50-day simple moving average is $17.96 and its 200 day simple moving average is $19.37.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. As a group, equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a share buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.